All articles tagged with #beta blockers
CNN reports that the traditional lifelong beta-blocker therapy after a heart attack is under scrutiny, with evidence suggesting that 1–2 years of use may suffice for many patients to reduce side effects and costs. CNN invites readers to submit questions for Dr. Sanjay Gupta to answer in an upcoming video.
A South Korean NEJM study found that among stable, low-risk heart-attack survivors, stopping beta-blockers after one year was as safe as continuing them for years: 58 events (7.2%) vs 74 (9%), deaths 2.4% vs 3.4%, recurrent heart attack 2.3% vs 2.6%, and heart-failure hospitalizations about 2% in both groups, with modest increases in BP/HR but SBP kept under 130. The results—alongside evolving guidelines—suggest lifelong beta-blockers may not be necessary for all, supporting shared decision-making and potential cost savings, though not all patients are candidates and further data are needed.
A large-scale study confirms that millions of people taking beta-blockers after a heart attack may be doing so unnecessarily, as the drugs show no benefit for patients with preserved heart function, potentially leading to changes in treatment guidelines and significant healthcare savings.
Some people use beta blockers, blood pressure-lowering drugs, to manage physical symptoms of anxiety like rapid heartbeat and trembling during performances or speeches.
New research warns that combining antidepressants and beta blockers may significantly increase the risk of dangerous heart conditions, such as low blood pressure and slow heart rate, though more studies are needed to confirm these findings.
The article discusses how beta blockers like propranolol can help alleviate physical symptoms of anxiety, especially in stressful situations, and shares personal and public examples of their use, while also noting their limitations and the importance of addressing underlying psychological issues.
Celebrities are increasingly using beta blockers like propranolol to manage anxiety symptoms during public appearances, as these drugs help reduce physical symptoms such as rapid heartbeat and trembling. Originally developed for heart conditions, beta blockers are now being used off-label for anxiety, though they mainly address physical rather than psychological aspects. While they are considered low-risk and non-addictive, they are not a cure for underlying anxiety issues and should be used cautiously under medical supervision.
Prescriptions for the heart medication propranolol are rising as it is increasingly used off-label to treat anxiety, with celebrities endorsing its use for calming nerves. The drug, approved for cardiovascular issues, works by blocking adrenaline effects, reducing physical symptoms of anxiety, and is considered safe and non-addictive when used responsibly. Medical professionals emphasize combining medication with natural stress-relief techniques for best results.
Many Hollywood stars are joking about using beta-blockers to manage stage fright during awards shows, with doctors noting their off-label use to prevent adrenaline from triggering anxiety symptoms. The article also discusses Giorgio Armani's rise to fame in Hollywood, largely thanks to his work on 'The Untouchables,' and highlights a creative font design inspired by Emily Brontë's 'Wuthering Heights' using a woman's bra as inspiration. These stories reveal the quirky and innovative ways celebrities and designers navigate fame and creativity.
Recent research challenges traditional heart attack treatments, suggesting clopidogrel may be safer and more effective than aspirin for long-term use, while beta-blockers could increase the risk of a second heart attack and mortality in women, prompting a reevaluation of treatment guidelines.
A large international study called the REBOOT trial has found that beta blockers, a common treatment for heart attack survivors with normal heart function, do not provide benefits and may increase risks for women, challenging decades of standard practice.
Recent research indicates that beta-blockers may not only be ineffective but potentially harmful for women with certain heart conditions, especially those with preserved left ventricular ejection fraction and on higher doses, highlighting the need for sex-specific treatment considerations.
Recent studies suggest that beta blockers, commonly prescribed after heart attacks, may no longer be beneficial for many patients, especially women with well-recovered hearts, and could even be harmful, prompting calls for more personalized treatment approaches.
A large international study called REBOOT found that beta-blockers may not provide benefits for most heart attack patients with preserved heart function, and could even be harmful to women, suggesting a need to revise current treatment guidelines.
The REBOOT trial found that beta blockers, a standard treatment for heart attack patients for over 40 years, provide no benefit for those with uncomplicated myocardial infarction and may be risky for women, potentially leading to a change in global clinical guidelines.